Reasons for failure of prevention of Toxoplasma encephalitis

AIDS

Volumn 10, Issue 5, 1996, Pages 509-513

  Van Delden, Christian ^b   Gabriel, Victor ^b   Sudre, Philippe ^b   Flepp, Markus ^a   Von Overbeck, Jan ^a   Hirschel, Bernard ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital Geneva ^*

Author keywords

AIDS; Prophylaxis; Toxoplasmosis

Indexed keywords

COTRIMOXAZOLE; SULFONAMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; ENCEPHALITIS; HUMAN; ILLNESS BEHAVIOR; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SWITZERLAND; TOXOPLASMOSIS; VOMITING;

EID: 0029969275     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199605000-00009     Document Type: Article

References (25)

1. Renold C, Sugar A, Chave JP, et al.: Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Medicine 1992, 71:224-239.
2. Oksenhendler E, Charreau I, Tournerie C, Azihary M, Carbon C, Aboulker J-P: Toxoplasma gondii infection in advanced HIV infection. AIDS 1994, 8:483-487.
3. Beaman MH, Luft BJL, Remington JS: Prophylaxis for toxoplasmosis in AIDS. Ann Intern Med 1992, 117:163-164.
4. Gallant JE, Moore R, Chaisson RE: Prophylaxis for opportunistic infections in patients with HIV infection. Ann Intern Med 1994, 120:932-944.
5. Richards FO, Kovacs JA, Luft BJ: Preventing toxoplasmic encephalitis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995, 21 (suppl 1):49-56.
6. Carr A, Tindall B, Brew BJ, et al.: Low dose trimethoprim-sulfamethoxazole prophylaxis for toxoplasmic encephalitis in AIDS. Ann Intern Med 1992, 117:106-111.
7. Rothman KJ: Matching. In Modern Epidemiology. Boston: Little, Brown and Company; 1986:237-282.
8. Hardy DW, Feinberg J, Finkelstein DM, et al.: A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992, 327:1842-1848.
9. Schneider MME, Hoepelman AIM, Karel JM, et al.: A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. N Engl J Med 1992, 327:1836-1840.
10. Podzamczer D, Santín M, Jimenez J, Casanova A, Bolao F, Gudiol GRF: Thrice-weekly cotrimoxazole is better than weekly dapsone-pyrimethamine for the primary prevention of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 1993, 7:501-506.
11. Opravil M, Hirschel B, Lazzarin A, et al.: Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1995, 20:531-541.
12. Girard PM, Landman R, Gaudebout C, et al.: Dapsone-pyrimethamine compared with aerosolized pentamidine as primary prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis in HIV infection. N Engl J Med 1993, 328:1514-1520.
13. Clotet B, Sirera G, Romeu J, et al.: Twice weekly dapsone-pyrimethamine for preventing PCP and cerebral toxoplasmosis. AIDS 1991, 5:601-602.
14. Leport C, Raffi F, Matheron, et al.: Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Am J Med 1988, 84:94-100.
15. Heald A, Flepp M, Chave JP, et al.: Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. Ann Intern Med 1991, 115:760-763.
16. Podzamczer D, Miro JM, Bolao F, et al.: Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients in patients with AIDS. Ann Intern Med 1995, 123:175-180.
17. Pedrol E, Gonazales-Clemente JM, Gatell JM, et al.: Central nervous system toxoplasmosis in AIDS patients: efficacy of an intermittent maintenance therapy. AIDS 1990, 4:511-517.
18. Sereni D, Bachmeyer C, Salmon D, et al.: Why does toxoplasmic encephalitis still occur? X International Conference on AIDS. Yokohama, August 1994 [abstract PB0628].
19. Saah AJ, Hoover DR, Peng Y, et al.: Predictors for failure of Pneumocystis carinii pneumonia prophylaxis. JAMA 1995, 273:1197-1202.
20. Wynn RF, Leen CLS, Brettle RP: Azithromycin for cerebral toxoplasmosis in AIDS. Lancet 1993, 341:243-244.
21. Kovacs J, Polis MA, Baird B, et al.: Evaluation of azitromycin or the combination of 566C80 and pyrimethamine in the treatment of toxoplasmosis. XIII International Conference on AIDS. Amsterdam, July 1992 [abstract PoB3199].
22. Durand J-M, Cretel E, Bagneres D, Guillemot E, Kaplanski C, Soubeyrand J: Failure of atovaquone in the treatment of cerebral toxoplasmosis. AIDS 1995, 9:812-813.
23. Carr A, Penny R, Cooper DA: Efficacy and safety of rechallenge with low-dose trimethoprim-sulfamethoxazole in previously hypersensitive HIV-infected patients. AIDS 1993, 7:65-71.
24. Moreno JN, Poblete RB, Maggio C, Gagnon S, Fischl MA: Rapid oral desensitization for sulfonamides in patients with the acquired immunodeficiency syndrome. Ann Allergy Asthma Immunol 1995, 74:140-146.
25. Gluckstein D, Ruskin J: Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were previously intolerant to TMP-SMZ. Clin Infect Dis 1995, 20:849-853.